Universal Vision Biotechnology Co., Ltd. Stock

Equities

3218

TW0003218004

Medical Equipment, Supplies & Distribution

End-of-day quote Taipei Exchange 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
246.5 TWD -3.52% Intraday chart for Universal Vision Biotechnology Co., Ltd. -8.53% -11.01%
Sales 2024 * 4.53B 139M Sales 2025 * 5.3B 163M Capitalization 20.88B 642M
Net income 2024 * 1.15B 35.49M Net income 2025 * - EV / Sales 2024 * 4.14 x
Net cash position 2024 * 2.12B 65.27M Net cash position 2025 * 2.55B 78.39M EV / Sales 2025 * 3.46 x
P/E ratio 2024 *
18.1 x
P/E ratio 2025 *
-
Employees 401
Yield 2024 *
3.42%
Yield 2025 *
4.1%
Free-Float 52.5%
More Fundamentals * Assessed data
Dynamic Chart
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Universal Vision Biotechnology Co., Ltd. Declares Cash Dividend, Payable on May 20, 2024 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Universal Vision Biotechnology Co., Ltd. Announces Cash Dividend, Payable on September 20, 2023 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Health Care Down on Mixed Earnings Prospects - Health Care Roundup DJ
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Universal Vision Biotechnology Co., Ltd. Announces Principal Financial and Accounting Officer Changes CI
Universal Vision Biotechnology Co., Ltd. Announces Change of the Principal Financial and Accounting Officer CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Universal Vision Biotechnology Co., Ltd. Announces Dividend, Payable on May 13, 2022 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day-3.52%
1 week-8.53%
Current month-9.21%
1 month-10.04%
3 months-12.59%
6 months-19.97%
Current year-11.01%
More quotes
1 week
246.50
Extreme 246.5
269.50
1 month
246.50
Extreme 246.5
277.00
Current year
246.50
Extreme 246.5
307.00
1 year
246.50
Extreme 246.5
412.74
3 years
198.11
Extreme 198.1132
432.08
5 years
26.46
Extreme 26.46
432.08
10 years
16.26
Extreme 16.2624
432.08
More quotes
Managers TitleAgeSince
Chief Executive Officer - 10-01-31
Director of Finance/CFO - 16-03-31
President - 03-06-01
Members of the board TitleAgeSince
President - 03-06-01
Chairman - 12-06-27
Director/Board Member 64 12-06-27
More insiders
Date Price Change Volume
24-04-19 246.5 -3.52% 685,975
24-04-18 255.5 -1.73% 265,332
24-04-17 260 +1.56% 429,621
24-04-16 256 -4.12% 1,260,508
24-04-15 267 -0.93% 642,248

End-of-day quote Taipei Exchange, April 18, 2024

More quotes
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD is a Taiwan-based company principally engaged in the trading of ophthalmic supplies and the provision of eye treatment and related medical services. The Company provides laser vision correction equipment and services, as well as the trading of medical drugs, optical glasses and contact lenses. In addition, the Company is involved in the leasing of medical places, the planning of clinic operation, as well as the provision of medical cosmetology services. The Company operates its businesses mainly in Taiwan market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
246.5 TWD
Average target price
313.8 TWD
Spread / Average Target
+27.28%
Consensus